Overview

A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy

Status:
Terminated
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the appropriate dose of AEZS-108 to treat patients with a tumor of the urinary system.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
AEterna Zentaris
Collaborators:
Miami VA Healthcare System
University of Miami
University of Miami Sylvester Comprehensive Cancer Center
Treatments:
Doxorubicin
Prolactin Release-Inhibiting Factors